Montalis (Montelukast Sodium)

Montelukast, the active ingredient in Montalis, is a leukotriene receptor antagonist presented as an oral dosage form for oral use. It treats asthma and allergic rhinitis by reducing inflammation and bronchoconstriction in patients of all ages.

GNH USA supplies Montalis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Montalis, a leukotriene receptor antagonist, is used to manage conditions driven by leukotriene‑mediated inflammation. - Asthma: improves control of chronic asthma and reduces frequency of exacerbations. - Allergic rhinitis: alleviates nasal congestion, sneezing and itching associated with seasonal allergies. - Exercise‑induced bronchoconstriction: prevents airway narrowing triggered by physical activity.

Montalis may cause a range of adverse reactions, which are categorized by frequency.

Common Side Effects: - Headache: mild to moderate pain often reported during treatment. - Abdominal pain: discomfort or cramps in the stomach area. - Cough: occasional irritation of the throat leading to coughing. - Sore throat: mild irritation or pain in the throat.

Serious or Rare Side Effects: - Mood changes: including depression, anxiety, or suicidal thoughts. - Stevens‑Johnson syndrome: severe skin reaction with blistering. - Angioedema: rapid swelling of the face, lips, or tongue that may affect breathing.

Before prescribing Montalis, clinicians should consider several safety measures. - Assess asthma control: ensure patient is on appropriate inhaled therapy before adding montelukast. - Monitor neuropsychiatric symptoms: watch for mood changes, depression, or suicidal ideation. - Use caution in hepatic impairment: dose adjustment may be required in patients with liver dysfunction. - Avoid in patients with known hypersensitivity to montelukast or any excipients. - Store at room temperature: keep in the original container, protect from moisture and light.

Montelukast can interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Ritonavir: may increase montelukast plasma concentrations. - Phenobarbital: may lower montelukast levels, reducing effectiveness. - Carbamazepine: can decrease montelukast exposure.

Moderate Interactions (Monitor Closely): - Warfarin: potential alteration of INR, requiring closer monitoring. - Theophylline: additive bronchospasm risk; observe respiratory status.